Suppr超能文献

[术前数字化。地高辛血浆水平的测定(作者译)]

[Preoperative digitalization. Measurement of digoxin plasma levels (author's transl)].

作者信息

Geiger H J, Rietbrock N

出版信息

Anaesthesist. 1976 Sep;25(9):405-17.

PMID:970596
Abstract

In a study of 233 patients from the department of surgery and anesthesiology taking digoxin preparations 64, per cent exhibit digoxin levels in the therapeutic range (0.6--1.5 ng/ml), 19 per cent had subtoxic concentrations ranged from 1.6--2.0 ng/ml and 7 per cent were in the toxic range (greater than 2 ng/ml). In patients treated with digoxin before admission to hospital subtherapeutic levels were most frequent. An average loading dose of digoxin 1 mg or more on one day may result in subtoxic and toxic digoxin levels on the second day, in patients receiving less than 1 mg digoxin daily an increasing frequency of plasma digoxin concentrations of 1.5 ng/ml or higher values was present on the third day. Averaged plasma digoxin concentrations were correlated with daily maintenance dose. There was, however, a wide individual variation in digoxin plasma concentrations. A low incidence of toxic digoxin plasma levels was observed in patients receiving a daily oral maintenance dose of 0.375 mg digoxin (Lanicor). For prophylactic digitalization of patients with normal renal and thyroid function the following schedules or statistical guidlines are proposed: Lanicor (bioavailability 60%): oral loading dose of 0.75 mg over two days, and then daily oral maintenance dose of 0.375 mg; Novodigal (bioavailability 80%): oral loading dose of 0.6 mg over two days and then daily oral maintenance dose of 0.3 mg; Digoxin i.v.: intravenous loading dose of 0.5 (0.4) mg over two days and then 0.25 (0.2) mg daily intravenous maintenance dose. For any patient needing treatment with digitalis glycosides therapy must be individual and dynamic. The reasons for toxic concentrations were frequently attributed to wrong dosage.

摘要

在一项对来自外科和麻醉科的233名服用地高辛制剂患者的研究中,64%的患者地高辛水平处于治疗范围(0.6 - 1.5纳克/毫升),19%的患者亚中毒浓度范围为1.6 - 2.0纳克/毫升,7%的患者处于中毒范围(大于2纳克/毫升)。入院前接受地高辛治疗的患者中,治疗水平以下最为常见。对于每日接受地高辛不足1毫克的患者,在一天给予平均负荷剂量1毫克或更多地高辛时,第二天可能会出现亚中毒和中毒的地高辛水平;在第三天,血浆地高辛浓度达到1.5纳克/毫升或更高值的频率增加。平均血浆地高辛浓度与每日维持剂量相关。然而,地高辛血浆浓度存在很大的个体差异。在每日口服维持剂量为0.375毫克地高辛(Lanicor)的患者中,观察到中毒地高辛血浆水平的发生率较低。对于肾功能和甲状腺功能正常的患者进行预防性洋地黄化,建议采用以下方案或统计指南:Lanicor(生物利用度60%):分两天口服负荷剂量0.75毫克,然后每日口服维持剂量0.375毫克;Novodigal(生物利用度80%):分两天口服负荷剂量0.6毫克,然后每日口服维持剂量0.3毫克;静脉用地高辛:分两天静脉注射负荷剂量0.5(0.4)毫克,然后每日静脉维持剂量0.25(0.2)毫克。对于任何需要使用洋地黄苷治疗的患者,治疗必须个体化且动态化。中毒浓度的原因常常归因于剂量错误。

相似文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验